Videos

Dr Mary Ann Picone shares her experience with telehealth care and provides resources for patients and physicians to manage multiple sclerosis treatment in the post-COVID era.

Gina Murdoch describes support programs that offer equipment, education, and services for the multiple sclerosis community.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University provided commentary on the need for clinicians to be transparent with patients with MS about potential differences in disease course. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending April 30, 2023. [WATCH TIME: 4 minutes]

The president elect of the Association of University Professors of Neurology discussed the benefits of working in neurology and the ways to not only attract new clinicians, but keep those already in the field. [WATCH TIME: 3 minutes]

The director of the Massachusetts General Hospital ALS Care Center discussed the importance of effective disease-modifying therapies for ALS and the potential of CNM-Au8 in the management of the disease. [WATCH TIME: 2 minutes]

The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University discusses the factors that affect the clinical care of LGBTQ+ patients with MS. [WATCH TIME: 4 minutes]

The professor of neurology at Boston University Chobanian & Avedisian School of Medicine talked about diagnostic tools and using memory aids for patients with cognitive impairment at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic discussed how additional sensors in seizure monitoring for patients with epilepsy may help better manage the risk of SUDEP. [WATCH TIME: 3 minutes]

The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University discussed a presentation at AAN 2023 characterizing the clinical and MRI features of Latinx with multiple sclerosis. [WATCH TIME: 4 minutes]

Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).

Experts discuss narcolepsy diagnosis and the challenges associated with it.

Stuart H. Isaacson, MD, FAAN, offers insight into the importance of tailoring care to the individual when it comes to managing patients with Parkinson disease.

A. Gordon Smith, MD, FAAN, talks about the importance of collaboration and education amid advances in myasthenia gravis treatment, from new formulations and routes of administration to innovative targets.

A. Gordon Smith, MD, FAAN, describes the landscape of investigational therapies for myasthenia gravis, including plasma cells, CAR-T, antigen-specific tolerance.

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

The head of the Stroke Program and Medical Director of the Comprehensive Stroke Center at Cleveland Clinic provided perspective on the ENRICH trial, the first positive surgical trial for intracerebral hemorrhage. [WATCH TIME: 5 minutes]

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller review the unmet needs in the treatment of NMOSD as well as hopes for the future.

Experts in neurology comment on disability and hospitalization rates of NMOSD, as well as how they approach treatment of NMOSD in clinical practice.

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, discuss barriers in accessing treatment for patients with RRMS, as well as a lack of appropriate biomarkers to monitor disease progression.

Experts in neurology review recent advances in the treatment landscape of relapse-remitting multiple sclerosis (RRMS) and the ever-present challenge of tailoring treatment to individual patients.

Multiple sclerosis expert Stephen Krieger, MD, discusses what can be inferred from the latest data on disease-modifying therapies as it pertains to cognition, and the importance of assessing cognitive performance over time.

The director of Cleveland Clinic’s Epilepsy Center provided an update on the World Brain Study, a large-scale, longitudinal study aimed to observe the early, underlying changes in neurological disorders. [WATCH TIME: 9 minutes]

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

The director of the Massachusetts General Hospital ALS Care Center talked about CNM-Au8 treatment across three populations, as well as the HEALEY ALS Platform Trial, at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.

Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.

Stephen Krieger, MD, speaks to the known effects of disease-modifying therapies for multiple sclerosis on cognitive function, among other interventions.